Drug × Cancer matrix

Drugs that target a gene either directly (oncogene) or via a synthetic-lethal partner (SLP) of a mutated tumour suppressor (TSG). Cell colour shows the strongest known status of that drug for that cancer subtype: approved clinical trial repositionable (potential reuse, no evidence yet) or blank.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Relationship
Show
Clear
Showing 200 of 808 drug-target rows in SSL view, for TSG = TOP1.
Drug TSG SLP (drug target) GBM LUAD SCLC LUSC OAC OSCC PDAC #
sunitinib TOP1 PDGFRA 7
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab TOP1 PDGFRA 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) TOP1 PDGFRA 4
trastuzumab emtansine TOP1 ERBB2 7
tucatinib TOP1 ERBB2 7
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine TOP1 TYMS 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib TOP1 WEE1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib TOP1 PDGFRA 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib TOP1 ERBB2 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib TOP1 CDK4 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib TOP1 LCK 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib TOP1 MST1R 3
afatinib TOP1 ERBB2 3
capecitabine, cisplatin TOP1 TYMS 3
crizotinib TOP1 MST1R 3
dec-205/ny-eso-1 fusion protein cdx-1401, laboratory biomarker analysis, pharmacological study, sirolimus TOP1 MTOR 3
gemcitabine TOP1 TYMS 3
mrtx849, pembrolizumab, cetuximab, afatinib TOP1 ERBB2 3
pembrolizumab, belzutifan, lenvatinib TOP1 PDGFRA 3
srf617, gemcitabine, albumin-bound paclitaxel, pembrolizumab TOP1 TYMS 3
abemaciclib TOP1 CDK4 7
capecitabine TOP1 TYMS 7
everolimus TOP1 MTOR 7
lapatinib TOP1 ERBB2 7
nintedanib TOP1 PDGFRA 7
palbociclib TOP1 CDK4 7
pazopanib TOP1 PDGFRA 7
regorafenib TOP1 PDGFRA 7
5-fu, atezolizumab, bevacizumab, gemcitabine, leucovorin, nab-paclitaxel, oxaliplatin, capecitabine, cisplatin TOP1 TYMS 2
ab598, zimberelimab, fluorouracil, leucovorin, oxaliplatin TOP1 TYMS 2
adavosertib, radiation therapy TOP1 WEE1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel TOP1 TYMS 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel TOP1 ERBB2 2
alvocidib, paclitaxel TOP1 CDK4 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan TOP1 TYMS 2
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine TOP1 TYMS 2
avelumab, lorlatanib, talazoparib, pemetrexed, axitinib, cmp 001, utomilumab, pf04518600 TOP1 TYMS 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment TOP1 TYMS 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment TOP1 LCK 2
bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil, therapeutic conventional surgery, laboratory biomarker analysis TOP1 TYMS 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib TOP1 CDK4 2
biospecimen collection, computed tomography, devimistat, fluorouracil, gemcitabine hydrochloride, hydroxychloroquine, magnetic resonance imaging TOP1 TYMS 2
biospecimen collection, computed tomography, pemetrexed TOP1 TYMS 2
bryostatin 1, paclitaxel TOP1 PRKCA 2
capecitabine, carboplatin, epirubicin hydrochloride TOP1 TYMS 2
capecitabine, docetaxel TOP1 TYMS 2
capecitabine, irinotecan hydrochloride TOP1 TYMS 2
capecitabine, oxaliplatin TOP1 TYMS 2
capecitabine, oxaliplatin, gene expression analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, quality-of-life assessment, radiation therapy TOP1 TYMS 2
capecitabine, temozolomide TOP1 TYMS 2
carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy TOP1 NEU1 2
carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy TOP1 TYMS 2
cetuximab, cisplatin, fluorouracil, conventional surgery TOP1 TYMS 2
chemotherapy, cisplatin, fluorouracil, low-let electron therapy, low-let photon therapy TOP1 TYMS 2
cisplatin, fluorouracil, conventional surgery, neoadjuvant therapy, radiation therapy TOP1 TYMS 2
cisplatin, fluorouracil, iressa, conventional surgery, radiation therapy TOP1 TYMS 2
cisplatin, fluorouracil, paclitaxel, conventional surgery, neoadjuvant therapy, radiation therapy TOP1 TYMS 2
cisplatin, fluorouracil, paclitaxel, surgical procedure, radiation therapy TOP1 TYMS 2
cisplatin, fluorouracil, surgical procedure, radiation therapy TOP1 TYMS 2
cisplatin, pemetrexed, gemcitabine, carboplatin, certolizumab, nivolumab TOP1 TYMS 2
cixutumumab, everolimus, laboratory biomarker analysis, octreotide acetate, pharmacological study TOP1 MTOR 2
cpt- 11, cisplatin, celecoxib, radiation, surgery TOP1 NEU1 2
durvalumab, tremelimumab, oxaliplatin, capecitabine, radiotherapy, paclitaxel, carboplatin, 5-fluorouracil (5-fu), leucovorin, docetaxel TOP1 TYMS 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab TOP1 ERBB2 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab TOP1 CDK4 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib TOP1 ERBB2 2
erlotinib hydrochloride, oxaliplatin, fluorouracil, radiation therapy, conventional surgery, immunohistochemistry staining method, positron emission tomography, computed tomography, laboratory biomarker analysis, gene expression analysis, fludeoxyglucose f 18 TOP1 TYMS 2
filgrastim, cisplatin, fluorouracil, paclitaxel, radiation therapy TOP1 TYMS 2
filgrastim, pegfilgrastim, cisplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy TOP1 TYMS 2
fluorouracil, gemcitabine hydrochloride, leucovorin calcium TOP1 TYMS 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, pharmacogenomic studies, pharmacological study TOP1 TYMS 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study TOP1 TYMS 2
fluorouracil, oxaliplatin, conventional surgery, radiation therapy TOP1 TYMS 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a TOP1 PDGFRA 2
inbrx-109, carboplatin, cisplatin, pemetrexed, 5-fluorouracil, irinotecan, temozolomide TOP1 TYMS 2
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib TOP1 TYMS 2
irinotecan, capecitabine TOP1 TYMS 2
ksq-001ex, interleukin-2, cyclophosphamide, fludarabine TOP1 DCK 2
laboratory biomarker analysis, oxaliplatin, pralatrexate TOP1 TYMS 2
lenvatinib, pembrolizumab TOP1 PDGFRA 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate TOP1 PDGFRA 2
ly4066434., cetuximab, nab paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, 5fluorouracil, carboplatin, cisplatin, pemetrexed, pembrolizumab TOP1 TYMS 2
m6620, cisplatin, capecitabine, radiotherapy TOP1 TYMS 2
mk-0482, pembrolizumab, paclitaxel, nab-paclitaxel, gemcitabine, carboplatin, pemetrexed TOP1 TYMS 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a TOP1 TYMS 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a TOP1 PDGFRA 2
motexafin gadolinium, radiation therapy TOP1 RRM2 2
nab-paclitaxel, gemcitabine TOP1 TYMS 2
nintedanib TOP1 LCK 2
nintedanib, pembrolizumab TOP1 PDGFRA 2
nintedanib, pembrolizumab TOP1 LCK 2
ociperlimab, tislelizumab, pemetrexed, paclitaxel, nab paclitaxel, carboplatin, cisplatin, etoposide, 5fluorouracil, oxaliplatin, capecitabine TOP1 TYMS 2
oleclumab, durvalumab, gemcitabine, nab-paclitaxel, oxaliplatin, folinic acid, 5-fu TOP1 TYMS 2
oxaliplatin, irinotecan hydrochloride, leucovorin calcium, fluorouracil, laboratory biomarker analysis TOP1 TYMS 2
pembrolizumab, lenvatinib TOP1 PDGFRA 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu TOP1 TYMS 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu TOP1 PDGFRA 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin TOP1 TYMS 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin TOP1 PDGFRA 2
pemetrexed, bevacizumab TOP1 TYMS 2
pralatrexate, docetaxel, fludeoxyglucose f 18, positron emission tomography TOP1 TYMS 2
radiotherapy targeted to the primary lesion, radiotherapy targeted to the metastatic lesions, anti-pd-1 monoclonal antibody, trastuzumab, chemotherapy, r0 total/subtotal gastrectomy with d2 lymphadenectomy, metastasectomy, local ablative therapies TOP1 ERBB2 2
regorafenib, laboratory biomarker analysis TOP1 PDGFRA 2
sar444881, pembrolizumab, cetuximab, carboplatin, pemetrexed TOP1 TYMS 2
sy-5609, fulvestrant, gemcitabine, nab-paclitaxel TOP1 TYMS 2
temsirolimus TOP1 MTOR 2
temsirolimus, laboratory biomarker analysis TOP1 MTOR 2
tislelizumab, pemetrexed TOP1 TYMS 2
trastuzumab TOP1 ERBB2 2
trastuzumab, abt-806, bemarituzumab, ramucirumab, nivolumab, standard cytotherapy TOP1 ERBB2 2
trastuzumab, tipifarnib TOP1 ERBB2 2
whole brain low dose radiotherapy, pemetrexed, sintilimab, chemotherapy TOP1 TYMS 2
pemetrexed TOP1 TYMS 7
ribociclib TOP1 CDK4 7
rosuvastatin TOP1 HMGCR 7
trilaciclib TOP1 CDK4 7
2b3-101, trastuzumab, 2b3-101 60 mg/m2 every 4 weeks, 2b3-101 50 mg/m2 every 3 weeks TOP1 ERBB2 1
3-dimensional conformal radiation therapy, bevacizumab, cisplatin, fluorouracil, intensity-modulated radiation therapy TOP1 TYMS 1
3-dimensional conformal radiation therapy, biospecimen collection, capecitabine, chemotherapy, computed tomography, erlotinib hydrochloride, fluorouracil, gemcitabine hydrochloride, intensity-modulated radiation therapy, magnetic resonance imaging, quality-of-life assessment, x-ray imaging TOP1 TYMS 1
3-dimensional conformal radiation therapy, motexafin gadolinium, temozolomide TOP1 RRM2 1
4-dimensional computed tomography, fluorouracil, gemcitabine hydrochloride, laboratory biomarker analysis, leucovorin calcium, nelfinavir mesylate, oregovomab, stereotactic body radiation therapy, therapeutic conventional surgery TOP1 TYMS 1
5-fu, leucovorin, docetaxel, oxaliplatin (flot), trastuzumab, post-operative treatment trastuzumab mono therapy TOP1 ERBB2 1
6,8-bis(benzylthio)octanoic acid, oxaliplatin, leucovorin calcium, irinotecan hydrochloride, fluorouracil, laboratory biomarker analysis TOP1 TYMS 1
7-hydroxystaurosporine, fluorouracil TOP1 TYMS 1
9-ing-41, retifanlimab, gemcitabine, abraxane TOP1 TYMS 1
abbv-400, budigalimab, fluorouracil, leucovorin, oxaliplatin TOP1 TYMS 1
abemaciclib, abemaciclib TOP1 CDK4 1
abemaciclib, bevacizumab TOP1 CDK4 1
abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf TOP1 CDK4 1
abemaciclib, ly3023414, gemcitabine, capecitabine TOP1 TYMS 1
abemaciclib, ly3023414, gemcitabine, capecitabine TOP1 CDK4 1
abemaciclib, ly3214996 TOP1 CDK4 1
abemaciclib, surgery TOP1 CDK4 1
abraxane (nab-paclitaxel), gemcitabine TOP1 TYMS 1
adavosertib TOP1 WEE1 1
adavosertib, laboratory biomarker analysis, pharmacological study, radiation therapy TOP1 WEE1 1
adavosertib, radiation therapy, temozolomide TOP1 WEE1 1
adct-601, gemcitabine TOP1 TYMS 1
adebrelimab, apatinib, tegafur TOP1 TYMS 1
adjuvant therapy, temozolomide, valproic acid, radiation therapy TOP1 CDKN1A 1
adriamycin, cyclophosphamide, vindesine, valproic acid TOP1 CDKN1A 1
aee788, everolimus TOP1 MTOR 1
afatinib dimaleate, capecitabine, laboratory biomarker analysis TOP1 TYMS 1
afatinib, biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging TOP1 ERBB2 1
afatinib, dasatinib, palbociclib, everolimus, olaparib TOP1 ERBB2 1
afatinib, dasatinib, palbociclib, everolimus, olaparib TOP1 MTOR 1
afatinib, dasatinib, palbociclib, everolimus, olaparib TOP1 CDK4 1
afatinib, dasatinib, palbociclib, everolimus, olaparib TOP1 LCK 1
afatinib, docetaxel, radiation therapy TOP1 ERBB2 1
afatinib, gefitinib TOP1 ERBB2 1
afatinib, irinotecan TOP1 ERBB2 1
ag-013736, gemcitabine, gemcitabine, placebo TOP1 TYMS 1
agen1423, botensilimab, gemcitabine, nab-paclitaxel TOP1 TYMS 1
ags-1c4d4, gemcitabine TOP1 TYMS 1
ak104, ak104, gemcitabine, nab-paclitaxel TOP1 TYMS 1
ak104, oxaliplatin, capecitabine TOP1 TYMS 1
ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, nab-paclitaxel, gemcitabine, nab-paclitaxel, gemcitabine TOP1 TYMS 1
akt inhibitor mk2206, fluorouracil, oxaliplatin, selumetinib TOP1 TYMS 1
albumin-bound paclitaxel (abi-007), gemcitabine TOP1 TYMS 1
aldesleukin, antibody therapy, fluorouracil, gemcitabine hydrochloride, irinotecan hydrochloride, laboratory biomarker analysis, leucovorin calcium, oxaliplatin, paclitaxel albumin-stabilized nanoparticle formulation, sargramostim TOP1 TYMS 1
aldesleukin, biopsy, biospecimen collection, computed tomography, cyclophosphamide, excisional biopsy, fludarabine, magnetic resonance imaging, standard treatment, therapeutic tumor infiltrating lymphocytes TOP1 DCK 1
alisertib, gemcitabine TOP1 TYMS 1
alpelisib, everolimus, exemestane TOP1 MTOR 1
alvocidib, docetaxel TOP1 CDK4 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis TOP1 CDK4 1
amg 193, gemcitabine, nab-paclitaxel, modified folfirinox TOP1 TYMS 1
amg 386 placebo, amg 386 10mg/kg, amg 386 3mg/kg, cisplatin, capecitabine, cisplatin, capecitabine, cisplatin, capecitabine TOP1 TYMS 1
amg 479, placebo, amg 479, gemcitabine TOP1 TYMS 1
aminolevulinic acid TOP1 ALAD 1
aminolevulinic acid, surgical resection TOP1 ALAD 1
andecaliximab, gemcitabine, nab-paclitaxel, carboplatin, pemetrexed, leucovorin, oxaliplatin, 5-fu, bevacizumab, irinotecan, paclitaxel TOP1 TYMS 1
apg-1387 for injection, gemcitabine, nab paclitaxel TOP1 TYMS 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib TOP1 MTOR 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib TOP1 CDK4 1
aprepitant, gemcitabine hydrochloride, capecitabine, fluorouracil, radiation therapy, questionnaire administration, quality-of-life assessment, nausea and vomiting therapy, management of therapy complications TOP1 TYMS 1
apx005m, nivolumab, nab-paclitaxel, gemcitabine TOP1 TYMS 1
arq 197, gemcitabine TOP1 TYMS 1
arsenic trioxide TOP1 CDKN1A 1
arsenic trioxide, radiation therapy TOP1 CDKN1A 1
arsenic trioxide, temozolomide, adjuvant therapy, intensity-modulated radiation therapy, radiation therapy TOP1 CDKN1A 1
ascorbate, nab paclitaxel, gemcitabine TOP1 TYMS 1
ascorbic acid, paclitaxel protein-bound, cisplatin, gemcitabine TOP1 TYMS 1
ascorbic acid, paclitaxel protein-bound, cisplatin, gemcitabine TOP1 DBH 1
askb589, oxaliplatin, capecitabine, tislelizumab, placebo TOP1 TYMS 1
atezolizumab, biospecimen collection, capecitabine, computed tomography, docetaxel, echocardiography, fluorouracil, leucovorin calcium, lymphadenectomy, magnetic resonance imaging, oxaliplatin, positron emission tomography, surgical procedure TOP1 TYMS 1
atezolizumab, conventional surgery, fluorouracil, oxaliplatin, tiragolumab TOP1 TYMS 1
atezolizumab, tivozanib TOP1 PDGFRA 1
atorvastatin, temozolomide, radiotherapy TOP1 HMGCR 1
atra, gemcitabine, nab-paclitaxel TOP1 TYMS 1
autologous mesothelin-specific tcr-t cells, cyclophosphamide, fludarabine, bendamustine TOP1 DCK 1
avastin (bevacizumab), gemcitabine, radiation therapy TOP1 TYMS 1
avelumab, oxaliplatin, 5-fluorouracil, leucovorin, capecitabine, best supportive care, oxaliplatin, 5-fluorouracil, leucovorin, capecitabine TOP1 TYMS 1
azacitidine, vorinostat, gemcitabine, busulfan, melphalan, dexamethasone, caphosol, glutamine, pyridoxine, rituximab TOP1 TYMS 1
azd0171, durvalumab, gemcitabine, nab-paclitaxel TOP1 TYMS 1
azd0901, 5-fluorouracil, leucovorin, l-leucovorin, irinotecan, nanoliposomal irinotecan, gemcitabine TOP1 TYMS 1
azd1775, gemcitabine, nab-paclitaxel TOP1 TYMS 1
azd6244, dacarbazine, erlotinib, docetaxel, temsirolimus TOP1 MTOR 1
bbi608, nab-paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, fluorouracil, mm-398 TOP1 TYMS 1
bendamustine, biopsy, biospecimen collection, computed tomography, cyclophosphamide, echocardiography, fludarabine, leukapheresis, magnetic resonance imaging, multigated acquisition scan, positron emission tomography, t-cell receptor-engineered t-cells TOP1 DCK 1
bethanechol, gemcitabine, nab-paclitaxel TOP1 TYMS 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable candidates from cansar.ai — these are potential drug-cancer reuse candidates, not evidence of efficacy.